ReviewGastroenterology clinics of North America2017
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Review in Gastroenterology clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease.Frontiers in cell and developmental biology · 2022Review
- Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD.Inflammatory bowel diseases · 2021Article
- Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2020Review
- Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.Inflammatory intestinal diseases · 2019Review
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.Rheumatology (Oxford, England) · 2019Review
- Thalidomide Prevented and Ameliorated Pathogenesis of Crohn's Disease in MiceFrontiers in pharmacology · 2019Article
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.Frontiers in pharmacology · 2019Review
- New biologics and small molecules in inflammatory bowel disease: an update.Therapeutic advances in gastroenterology · 2019Review
- Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.Inflammatory bowel diseases · 2018Review
- Total flavone ofWorld journal of gastroenterology · 2018Article
- Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease.Current treatment options in gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There is an ongoing, unmet need for effective therapies for Crohn's disease. Treatments for Crohn's disease continue to evolve from the traditional biologics to novel small molecules, with targeted mechanisms directed toward pathways that are dysregulated in Crohn's disease. There are multiple emerging mechanisms of action, including Janus kinase inhibition, Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.